It takes biopharma companies over 10 years, at a cost of over $2 billion and with a failure rate of over 90%, to deliver a new drug to patients. The Market to Molecule (M2M) value stream process, which biopharma companies must apply to bring new drugs to patients, is resource-intensive,Continue Reading
This post is co-written with Kim Nguyen and Shyam Banuprakash from Clario. Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for life sciences companies seeking to bring new therapies to patients. Since Clario’s founding more than 50 years ago, theContinue Reading
Research papers and engineering documents often contain a wealth of information in the form of mathematical formulas, charts, and graphs. Navigating these unstructured documents to find relevant information can be a tedious and time-consuming task, especially when dealing with large volumes of data. However, by using Anthropic’s Claude on AmazonContinue Reading
Harnessing the power of big data has become increasingly critical for businesses looking to gain a competitive edge. From deriving insights to powering generative artificial intelligence (AI)-driven applications, the ability to efficiently process and analyze large datasets is a vital capability. However, managing the complex infrastructure required for big dataContinue Reading
Innovations in artificial intelligence (AI) and machine learning (ML) are causing organizations to take a fresh look at the possibilities these technologies can offer. As you aim to bring your proofs of concept to production at an enterprise scale, you may experience challenges aligning with the strict security compliance requirementsContinue Reading
Maksim Labkouski/iStock via Getty Images R1 RCM (NASDAQ:RCM) jumped 10% in after hours trading as TCP-ASC said it’s in the process of finalizing a proposal to purchase the outstanding shares of the company not owned by the holder. The proposal is for a higher price than the $13.25 described inContinue Reading
SOMKID THONGDEE/iStock via Getty Images Exela Technologies (NASDAQ:XELA) on Monday said that its Board of Directors has authorized the company to consider a spin-off of its wholly owned subsidiary, Exela Technologies BPA, to Exela stockholders. The potential spin-off, if completed, would likely be structured so that all Exela (XELA) stockholdersContinue Reading
